Patrys Limited
Patrys Limited (PAB.AX) Stock Competitors & Peer Comparison
See (PAB.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PAB.AX | A$0.00 | +0.00% | 9.2M | N/A | N/A | N/A |
| CSL.AX | A$226.00 | +2.38% | 109.4B | 23.64 | A$9.56 | +1.88% |
| TLX.AX | A$18.10 | +6.97% | 6.1B | 129.29 | A$0.14 | N/A |
| MSB.AX | A$2.37 | +2.16% | 3B | -12.47 | -A$0.19 | N/A |
| NEU.AX | A$17.33 | +2.36% | 2.1B | 15.90 | A$1.09 | N/A |
| CU6.AX | A$3.54 | +2.61% | 1.3B | -22.12 | -A$0.16 | N/A |
| PYC.AX | A$1.32 | +3.53% | 769.9M | -12.00 | -A$0.11 | N/A |
| OPT.AX | A$0.60 | +0.00% | 738.8M | -1.40 | -A$0.43 | N/A |
| CUV.AX | A$11.99 | +2.74% | 601M | 15.57 | A$0.77 | +0.42% |
| IMM.AX | A$0.25 | +0.00% | 359.6M | -8.17 | -A$0.03 | N/A |
Stock Comparison
PAB.AX vs CSL.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, CSL.AX has a market cap of 109.4B. Regarding current trading prices, PAB.AX is priced at A$0.00, while CSL.AX trades at A$226.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas CSL.AX's P/E ratio is 23.64. In terms of profitability, PAB.AX's ROE is -1.14%, compared to CSL.AX's ROE of +0.17%. Regarding short-term risk, PAB.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CSL.AX's competition here
PAB.AX vs TLX.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, TLX.AX has a market cap of 6.1B. Regarding current trading prices, PAB.AX is priced at A$0.00, while TLX.AX trades at A$18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas TLX.AX's P/E ratio is 129.29. In terms of profitability, PAB.AX's ROE is -1.14%, compared to TLX.AX's ROE of +0.10%. Regarding short-term risk, PAB.AX is less volatile compared to TLX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check TLX.AX's competition here
PAB.AX vs MSB.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, MSB.AX has a market cap of 3B. Regarding current trading prices, PAB.AX is priced at A$0.00, while MSB.AX trades at A$2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas MSB.AX's P/E ratio is -12.47. In terms of profitability, PAB.AX's ROE is -1.14%, compared to MSB.AX's ROE of -0.22%. Regarding short-term risk, PAB.AX is less volatile compared to MSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check MSB.AX's competition here
PAB.AX vs NEU.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, NEU.AX has a market cap of 2.1B. Regarding current trading prices, PAB.AX is priced at A$0.00, while NEU.AX trades at A$17.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas NEU.AX's P/E ratio is 15.90. In terms of profitability, PAB.AX's ROE is -1.14%, compared to NEU.AX's ROE of +0.49%. Regarding short-term risk, PAB.AX is less volatile compared to NEU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NEU.AX's competition here
PAB.AX vs CU6.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, CU6.AX has a market cap of 1.3B. Regarding current trading prices, PAB.AX is priced at A$0.00, while CU6.AX trades at A$3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas CU6.AX's P/E ratio is -22.12. In terms of profitability, PAB.AX's ROE is -1.14%, compared to CU6.AX's ROE of -0.36%. Regarding short-term risk, PAB.AX is less volatile compared to CU6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CU6.AX's competition here
PAB.AX vs PYC.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, PYC.AX has a market cap of 769.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while PYC.AX trades at A$1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas PYC.AX's P/E ratio is -12.00. In terms of profitability, PAB.AX's ROE is -1.14%, compared to PYC.AX's ROE of -0.71%. Regarding short-term risk, PAB.AX is less volatile compared to PYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PYC.AX's competition here
PAB.AX vs OPT.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, OPT.AX has a market cap of 738.8M. Regarding current trading prices, PAB.AX is priced at A$0.00, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas OPT.AX's P/E ratio is -1.40. In terms of profitability, PAB.AX's ROE is -1.14%, compared to OPT.AX's ROE of +5.21%. Regarding short-term risk, PAB.AX is less volatile compared to OPT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check OPT.AX's competition here
PAB.AX vs CUV.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, CUV.AX has a market cap of 601M. Regarding current trading prices, PAB.AX is priced at A$0.00, while CUV.AX trades at A$11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas CUV.AX's P/E ratio is 15.57. In terms of profitability, PAB.AX's ROE is -1.14%, compared to CUV.AX's ROE of +0.18%. Regarding short-term risk, PAB.AX is less volatile compared to CUV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CUV.AX's competition here
PAB.AX vs IMM.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, IMM.AX has a market cap of 359.6M. Regarding current trading prices, PAB.AX is priced at A$0.00, while IMM.AX trades at A$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas IMM.AX's P/E ratio is -8.17. In terms of profitability, PAB.AX's ROE is -1.14%, compared to IMM.AX's ROE of -0.24%. Regarding short-term risk, PAB.AX is less volatile compared to IMM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check IMM.AX's competition here
PAB.AX vs OCC.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, OCC.AX has a market cap of 292.5M. Regarding current trading prices, PAB.AX is priced at A$0.00, while OCC.AX trades at A$1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas OCC.AX's P/E ratio is -59.75. In terms of profitability, PAB.AX's ROE is -1.14%, compared to OCC.AX's ROE of -0.27%. Regarding short-term risk, PAB.AX is less volatile compared to OCC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check OCC.AX's competition here
PAB.AX vs BOT.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, BOT.AX has a market cap of 284.4M. Regarding current trading prices, PAB.AX is priced at A$0.00, while BOT.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas BOT.AX's P/E ratio is -7.25. In terms of profitability, PAB.AX's ROE is -1.14%, compared to BOT.AX's ROE of -0.39%. Regarding short-term risk, PAB.AX is less volatile compared to BOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BOT.AX's competition here
PAB.AX vs DXB.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, DXB.AX has a market cap of 279.1M. Regarding current trading prices, PAB.AX is priced at A$0.00, while DXB.AX trades at A$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas DXB.AX's P/E ratio is -11.62. In terms of profitability, PAB.AX's ROE is -1.14%, compared to DXB.AX's ROE of -1.84%. Regarding short-term risk, PAB.AX is less volatile compared to DXB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check DXB.AX's competition here
PAB.AX vs RAC.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, RAC.AX has a market cap of 205M. Regarding current trading prices, PAB.AX is priced at A$0.00, while RAC.AX trades at A$1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas RAC.AX's P/E ratio is -23.60. In terms of profitability, PAB.AX's ROE is -1.14%, compared to RAC.AX's ROE of -0.39%. Regarding short-term risk, PAB.AX is less volatile compared to RAC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RAC.AX's competition here
PAB.AX vs EZZ.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, EZZ.AX has a market cap of 128.3M. Regarding current trading prices, PAB.AX is priced at A$0.00, while EZZ.AX trades at A$2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas EZZ.AX's P/E ratio is 12.95. In terms of profitability, PAB.AX's ROE is -1.14%, compared to EZZ.AX's ROE of +0.40%. Regarding short-term risk, PAB.AX is less volatile compared to EZZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check EZZ.AX's competition here
PAB.AX vs BIO.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, BIO.AX has a market cap of 123.5M. Regarding current trading prices, PAB.AX is priced at A$0.00, while BIO.AX trades at A$0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas BIO.AX's P/E ratio is -56.00. In terms of profitability, PAB.AX's ROE is -1.14%, compared to BIO.AX's ROE of +0.08%. Regarding short-term risk, PAB.AX is less volatile compared to BIO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BIO.AX's competition here
PAB.AX vs RCE.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, RCE.AX has a market cap of 122.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while RCE.AX trades at A$0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas RCE.AX's P/E ratio is -4.72. In terms of profitability, PAB.AX's ROE is -1.14%, compared to RCE.AX's ROE of +2.47%. Regarding short-term risk, PAB.AX is less volatile compared to RCE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RCE.AX's competition here
PAB.AX vs PAR.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, PAR.AX has a market cap of 121.2M. Regarding current trading prices, PAB.AX is priced at A$0.00, while PAR.AX trades at A$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas PAR.AX's P/E ratio is -6.10. In terms of profitability, PAB.AX's ROE is -1.14%, compared to PAR.AX's ROE of -0.54%. Regarding short-term risk, PAB.AX is less volatile compared to PAR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PAR.AX's competition here
PAB.AX vs ATH.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ATH.AX has a market cap of 119.7M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ATH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ATH.AX's P/E ratio is -1.30. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ATH.AX's ROE of -1.83%. Regarding short-term risk, PAB.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ATH.AX's competition here
PAB.AX vs PAA.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, PAB.AX is less volatile compared to PAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PAA.AX's competition here
PAB.AX vs ALA.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ALA.AX has a market cap of 101.4M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ALA.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ALA.AX's P/E ratio is -8.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ALA.AX's ROE of -0.55%. Regarding short-term risk, PAB.AX is less volatile compared to ALA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ALA.AX's competition here
PAB.AX vs ACW.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ACW.AX has a market cap of 95.3M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ACW.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ACW.AX's P/E ratio is -3.00. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ACW.AX's ROE of -0.44%. Regarding short-term risk, PAB.AX is less volatile compared to ACW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ACW.AX's competition here
PAB.AX vs ATX.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ATX.AX has a market cap of 90M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ATX.AX trades at A$0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ATX.AX's P/E ratio is -9.25. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ATX.AX's ROE of -0.51%. Regarding short-term risk, PAB.AX is less volatile compared to ATX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ATX.AX's competition here
PAB.AX vs AGN.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, AGN.AX has a market cap of 87.4M. Regarding current trading prices, PAB.AX is priced at A$0.00, while AGN.AX trades at A$0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas AGN.AX's P/E ratio is -13.60. In terms of profitability, PAB.AX's ROE is -1.14%, compared to AGN.AX's ROE of -0.39%. Regarding short-term risk, PAB.AX is less volatile compared to AGN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check AGN.AX's competition here
PAB.AX vs IMU.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, IMU.AX has a market cap of 79.3M. Regarding current trading prices, PAB.AX is priced at A$0.00, while IMU.AX trades at A$0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas IMU.AX's P/E ratio is -0.46. In terms of profitability, PAB.AX's ROE is -1.14%, compared to IMU.AX's ROE of -1.42%. Regarding short-term risk, PAB.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check IMU.AX's competition here
PAB.AX vs RAD.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, RAD.AX has a market cap of 70.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while RAD.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas RAD.AX's P/E ratio is -0.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to RAD.AX's ROE of -1.03%. Regarding short-term risk, PAB.AX is less volatile compared to RAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RAD.AX's competition here
PAB.AX vs ADO.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ADO.AX has a market cap of 62.2M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ADO.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ADO.AX's P/E ratio is -2.30. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ADO.AX's ROE of -1.34%. Regarding short-term risk, PAB.AX is less volatile compared to ADO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ADO.AX's competition here
PAB.AX vs NYR.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, NYR.AX has a market cap of 56.8M. Regarding current trading prices, PAB.AX is priced at A$0.00, while NYR.AX trades at A$0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas NYR.AX's P/E ratio is -13.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to NYR.AX's ROE of -0.73%. Regarding short-term risk, PAB.AX is less volatile compared to NYR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NYR.AX's competition here
PAB.AX vs ILA.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ILA.AX has a market cap of 56.8M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ILA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ILA.AX's P/E ratio is -7.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ILA.AX's ROE of -1.20%. Regarding short-term risk, PAB.AX is less volatile compared to ILA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ILA.AX's competition here
PAB.AX vs SPL.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, SPL.AX has a market cap of 56.5M. Regarding current trading prices, PAB.AX is priced at A$0.00, while SPL.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas SPL.AX's P/E ratio is -4.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to SPL.AX's ROE of -0.49%. Regarding short-term risk, PAB.AX is less volatile compared to SPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check SPL.AX's competition here
PAB.AX vs NSB.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, NSB.AX has a market cap of 54.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while NSB.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas NSB.AX's P/E ratio is 16.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to NSB.AX's ROE of +0.23%. Regarding short-term risk, PAB.AX is less volatile compared to NSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NSB.AX's competition here
PAB.AX vs PIQ.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, PIQ.AX has a market cap of 51.6M. Regarding current trading prices, PAB.AX is priced at A$0.00, while PIQ.AX trades at A$0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas PIQ.AX's P/E ratio is -5.25. In terms of profitability, PAB.AX's ROE is -1.14%, compared to PIQ.AX's ROE of -0.96%. Regarding short-term risk, PAB.AX is less volatile compared to PIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PIQ.AX's competition here
PAB.AX vs CYP.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, CYP.AX has a market cap of 47.5M. Regarding current trading prices, PAB.AX is priced at A$0.00, while CYP.AX trades at A$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas CYP.AX's P/E ratio is -4.20. In terms of profitability, PAB.AX's ROE is -1.14%, compared to CYP.AX's ROE of -0.95%. Regarding short-term risk, PAB.AX is less volatile compared to CYP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CYP.AX's competition here
PAB.AX vs PTX.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, PTX.AX has a market cap of 44.7M. Regarding current trading prices, PAB.AX is priced at A$0.00, while PTX.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas PTX.AX's P/E ratio is -4.30. In terms of profitability, PAB.AX's ROE is -1.14%, compared to PTX.AX's ROE of -0.42%. Regarding short-term risk, PAB.AX is less volatile compared to PTX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PTX.AX's competition here
PAB.AX vs NOX.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, NOX.AX has a market cap of 32.1M. Regarding current trading prices, PAB.AX is priced at A$0.00, while NOX.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas NOX.AX's P/E ratio is -11.00. In terms of profitability, PAB.AX's ROE is -1.14%, compared to NOX.AX's ROE of -0.47%. Regarding short-term risk, PAB.AX is less volatile compared to NOX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NOX.AX's competition here
PAB.AX vs LCT.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, PAB.AX is priced at A$0.00, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -1.14%, compared to LCT.AX's ROE of -0.54%. Regarding short-term risk, PAB.AX and LCT.AX have similar daily volatility (0.00).Check LCT.AX's competition here
PAB.AX vs NC6.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, NC6.AX has a market cap of 23.8M. Regarding current trading prices, PAB.AX is priced at A$0.00, while NC6.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas NC6.AX's P/E ratio is -7.80. In terms of profitability, PAB.AX's ROE is -1.14%, compared to NC6.AX's ROE of +3.42%. Regarding short-term risk, PAB.AX is less volatile compared to NC6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NC6.AX's competition here
PAB.AX vs IMC.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, IMC.AX has a market cap of 19.3M. Regarding current trading prices, PAB.AX is priced at A$0.00, while IMC.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas IMC.AX's P/E ratio is -2.40. In terms of profitability, PAB.AX's ROE is -1.14%, compared to IMC.AX's ROE of -0.64%. Regarding short-term risk, PAB.AX is less volatile compared to IMC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check IMC.AX's competition here
PAB.AX vs AVE.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, AVE.AX has a market cap of 19M. Regarding current trading prices, PAB.AX is priced at A$0.00, while AVE.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas AVE.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -1.14%, compared to AVE.AX's ROE of -0.83%. Regarding short-term risk, PAB.AX and AVE.AX have similar daily volatility (0.00).Check AVE.AX's competition here
PAB.AX vs KZA.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, PAB.AX's ROE is -1.14%, compared to KZA.AX's ROE of -1.33%. Regarding short-term risk, PAB.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check KZA.AX's competition here
PAB.AX vs BTC.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, BTC.AX has a market cap of 18.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas BTC.AX's P/E ratio is 5.80. In terms of profitability, PAB.AX's ROE is -1.14%, compared to BTC.AX's ROE of +0.58%. Regarding short-term risk, PAB.AX and BTC.AX have similar daily volatility (0.00).Check BTC.AX's competition here
PAB.AX vs TRP.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, TRP.AX has a market cap of 17.5M. Regarding current trading prices, PAB.AX is priced at A$0.00, while TRP.AX trades at A$0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas TRP.AX's P/E ratio is -4.14. In terms of profitability, PAB.AX's ROE is -1.14%, compared to TRP.AX's ROE of -0.26%. Regarding short-term risk, PAB.AX and TRP.AX have similar daily volatility (0.00).Check TRP.AX's competition here
PAB.AX vs MDC.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, PAB.AX is priced at A$0.00, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas MDC.AX's P/E ratio is -0.01. In terms of profitability, PAB.AX's ROE is -1.14%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, PAB.AX and MDC.AX have similar daily volatility (0.00).Check MDC.AX's competition here
PAB.AX vs BNO.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, PAB.AX is priced at A$0.00, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, PAB.AX's ROE is -1.14%, compared to BNO.AX's ROE of -0.05%. Regarding short-term risk, PAB.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BNO.AX's competition here
PAB.AX vs CHM.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, CHM.AX has a market cap of 9.8M. Regarding current trading prices, PAB.AX is priced at A$0.00, while CHM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas CHM.AX's P/E ratio is -0.15. In terms of profitability, PAB.AX's ROE is -1.14%, compared to CHM.AX's ROE of -4.24%. Regarding short-term risk, PAB.AX and CHM.AX have similar daily volatility (0.00).Check CHM.AX's competition here
PAB.AX vs MEM.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, MEM.AX has a market cap of 7.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while MEM.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas MEM.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -1.14%, compared to MEM.AX's ROE of -0.79%. Regarding short-term risk, PAB.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check MEM.AX's competition here
PAB.AX vs IXC.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, IXC.AX has a market cap of 7.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while IXC.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas IXC.AX's P/E ratio is -10.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to IXC.AX's ROE of +0.02%. Regarding short-term risk, PAB.AX and IXC.AX have similar daily volatility (0.00).Check IXC.AX's competition here
PAB.AX vs BGT.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, BGT.AX has a market cap of 6.4M. Regarding current trading prices, PAB.AX is priced at A$0.00, while BGT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas BGT.AX's P/E ratio is -2.10. In terms of profitability, PAB.AX's ROE is -1.14%, compared to BGT.AX's ROE of -1.15%. Regarding short-term risk, PAB.AX and BGT.AX have similar daily volatility (0.00).Check BGT.AX's competition here
PAB.AX vs ACR.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ACR.AX has a market cap of 6.1M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ACR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ACR.AX's P/E ratio is -0.75. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ACR.AX's ROE of -1.79%. Regarding short-term risk, PAB.AX and ACR.AX have similar daily volatility (0.00).Check ACR.AX's competition here
PAB.AX vs ZLD.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ZLD.AX has a market cap of 4.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ZLD.AX trades at A$0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ZLD.AX's P/E ratio is -0.99. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ZLD.AX's ROE of +0.75%. Regarding short-term risk, PAB.AX is less volatile compared to ZLD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ZLD.AX's competition here
PAB.AX vs 1AD.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, 1AD.AX has a market cap of 4.6M. Regarding current trading prices, PAB.AX is priced at A$0.00, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas 1AD.AX's P/E ratio is -0.40. In terms of profitability, PAB.AX's ROE is -1.14%, compared to 1AD.AX's ROE of -4.64%. Regarding short-term risk, PAB.AX is less volatile compared to 1AD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check 1AD.AX's competition here
PAB.AX vs BIT.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, BIT.AX has a market cap of 4M. Regarding current trading prices, PAB.AX is priced at A$0.00, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas BIT.AX's P/E ratio is -0.30. In terms of profitability, PAB.AX's ROE is -1.14%, compared to BIT.AX's ROE of -13.17%. Regarding short-term risk, PAB.AX and BIT.AX have similar daily volatility (0.00).Check BIT.AX's competition here
PAB.AX vs RGS.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, PAB.AX is priced at A$0.00, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, PAB.AX's ROE is -1.14%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, PAB.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RGS.AX's competition here
PAB.AX vs VBS.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, VBS.AX has a market cap of 3.2M. Regarding current trading prices, PAB.AX is priced at A$0.00, while VBS.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas VBS.AX's P/E ratio is -1.50. In terms of profitability, PAB.AX's ROE is -1.14%, compared to VBS.AX's ROE of -2.39%. Regarding short-term risk, PAB.AX and VBS.AX have similar daily volatility (0.00).Check VBS.AX's competition here
PAB.AX vs HXL.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, HXL.AX has a market cap of 2.2M. Regarding current trading prices, PAB.AX is priced at A$0.00, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas HXL.AX's P/E ratio is -1.30. In terms of profitability, PAB.AX's ROE is -1.14%, compared to HXL.AX's ROE of -0.53%. Regarding short-term risk, PAB.AX and HXL.AX have similar daily volatility (0.00).Check HXL.AX's competition here
PAB.AX vs EX1.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, PAB.AX is priced at A$0.00, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, PAB.AX's ROE is -1.14%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, PAB.AX and EX1.AX have similar daily volatility (0.00).Check EX1.AX's competition here
PAB.AX vs ANR.AX Comparison August 2025
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 9.2M. In comparison, ANR.AX has a market cap of 1.7M. Regarding current trading prices, PAB.AX is priced at A$0.00, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of N/A, whereas ANR.AX's P/E ratio is -0.80. In terms of profitability, PAB.AX's ROE is -1.14%, compared to ANR.AX's ROE of -1.42%. Regarding short-term risk, PAB.AX and ANR.AX have similar daily volatility (0.00).Check ANR.AX's competition here